Skip to content
TrialScanner

NCT05726864

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Phase 1/Phase 2Active, not recruitingELTXLead

Registry record

Lead sponsor
Elicio Therapeutics
Conditions
Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; KRAS G12D; KRAS G12R; KRAS G12V
Primary completion
Apr 20, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05726864 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.